Patient Recruitment Applications & Studies

91. A High Unmet Need That No One Wanted To Talk About 3/2/2020

    What do you do when patients are too embarrassed to talk about what’s wrong with them? Recruiting “hidden” patient groups for rare disease studies is always challenging, and flexibility is the only constant.

92. Clinical Trial Start To Finish …. That Was Easy 2/26/2020

    A sponsor needed to test a new nonsteroidal anti-inflammatory drug (NSAID). Working with an experienced CRO allowed them to line up the 40 best sites in the country for this type of analgesia study and have the best training and tools at each site.

93. CRO Clears Path For Success For Rosacea Trial With Enrollment Hurdles 2/24/2020

    Two large, parallel trials were being conducted with 107 sites spread across the United States for a topical drug to treat rosacea. They were challenged to come up with an advertising strategy to needed to attract more than 1,400 subjects fast enough to meet the aggressive schedule.

94. Dealing With the Unexpected: Surprisingly Fast Clinical Trial Enrollment 2/10/2020

    Faced with an unusual situation with patients rushing to enroll almost as soon as word of the study got out, this CRO quickly recognized the issue and ramped up staffing, right-sized other locations in the study, and collaborated effectively with all parties involved to deliver conclusive, positive results eight months ahead of time.

95. Phase III Rare Disease Rescue 1/2/2020

    A small biotech with limited internal capacity outsourced a phase III clinical program in patients with Necrotizing Soft Tissue Infections. After nearly 16 months, patient enrollment was still a major challenge, the study was over budget and CRO staff turnover on the project was extremely high. Catalyst provided a blinded and unblinded monitoring team that reported into the Sponsor’s CTM using Catalyst’s SOPs allowing the Sponsor to retain control of their program.

96. Evidence Generation Strategic Partnership For Heart Failure Studies 12/9/2019

    Read how a pharmaceutical support services company helped a large pharmaceutical company manage a portfolio of 5 heart failure studies, with over 500 investigator sites and 7,000 patients, to accompany an evidence generation program for a new product launch.

97. Large Global Phase III Clinical Trial In Metastatic Colorectal Carcinoma (mCRC) 11/25/2019

    UBC was tasked with managing a large global phase III clinical trial in patients with mCRC refractory to standard chemotherapies. Read how patient enrollment was completed 3 months ahead of schedule and database lock 3.5 months ahead of schedule.

98. Enrollment Goals Exceeded Through High Touch, High Tech For A Dermatology Study Of Adolescent Patients 11/25/2019

    UBC was selected by a large biopharmaceutical company to manage a U.S.- based Phase IV randomized, placebo controlled clinical trial of patients with severe acne. As a result of UBC’s innovative services, not only was the enrollment goal achieved, but it was exceeded by 60%

99. 510(k) Study Of Respiratory Diagnostic 10/22/2019

    A sponsor had to conclude discussions with regulators and complete a variety of logistical arrangements and was left with an unusually brief period between study startup and the target period for sample collection – fall flu season. Read what risk management and mitigation strategies were used to ensure that site selection and startup happened quickly as to not miss flu season, what procedures were put in place so no samples were lost, other steps taken allowing the study to meet all of its goals.

100. Complete Response: Lymphoma Trial A Success For Five Patients 10/2/2019

     Read about a trans-Atlantic study that evaluated an antibody for treatment of B-cell non-Hodgkins lymphoma that overcame patient recruiting challenges and succeeded beyond expectations in the form of five patients.